Legal Fight over Gene Patents in AMP vs. Myriad Case to Be Subject of Oral Hearings at the Supreme Court, Just Months after Its Ruling in Prometheus Case

Both pathology profession and biotech industry have much at stake in how Supreme Court rules in this important case involving the patentability of genes Legal challenges to gene patents are a high interest topic among pathologists and clinical laboratory scientists who perform genetic testing. Two high profile cases involving gene patents were accepted by the Supreme Court. A ruling was made in one case and the second case is continuing. The Supreme Court issued a ruling in one case, titled...

Decisions in Prometheus, Myriad, and Classen Cases Help Clarify Patent Eligibility Requirements for Genetic Lab Tests and Molecular Diagnostics

Court rulings in several controversial patenting cases are largely consistent Recent decisions from the U.S. Court of Appeals for the Federal Circuit (CAFC) offer some much-needed clarity in the controversial issues surrounding the legality of life sciences patents. This will be of interest to pathologists and medical laboratory managers, because many clinical laboratories and pathology groups must pay royalties to patent-holders for rights to use the technologies. There are multiple legal...

GE Healthcare Pays $587 Million to Purchase Clarient, the Specialty Pathology and Cancer Testing Firm

GE’s Acquisition Considered A Sign Of More Deals To Come In The Clinical Laboratory Industry Here’s more confirmation that anatomic pathology continues to be a big target on the radar screen of big healthcare corporations and Wall Street investors. Today, GE Healthcare, a unit of General Electric Company (NYSE: GE), disclosed it will pay $587 million to acquire Clarient, Inc. (NASDAQ: CLRT), the medical testing laboratory. For pathologists and clinical laboratory managers, this is...